Alzamend Neuro Reports $2.7 Million Net Loss and Increased Operating Expenses in Latest 10-Q Filing

Alzamend Neuro, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending July 31, 2025. The company, which focuses on developing treatments for Alzheimer’s disease and other mental health disorders, recorded a net loss of $2.7 million, a substantial increase from the $974,411 loss reported in the same period last year. This represents a 177% increase in net loss year-over-year. The company did not generate any revenue during the quarter, consistent with its previous fiscal periods, as it remains in the clinical development stage for its two primary product candidates, AL001 and ALZN002.

Total operating expenses for the quarter reached $2.7 million, a significant rise of 181% compared to $962,405 in the prior year. The increase was primarily driven by research and development expenses, which surged to $1.7 million from $206,571, reflecting the company's intensified focus on clinical trials, particularly for AL001. General and administrative expenses also rose to $959,334, up from $755,834, largely due to increased professional fees and marketing costs. The company’s cash position improved, with cash and cash equivalents totaling $5.6 million as of July 31, 2025, compared to $3.9 million at the end of April 2025.

In terms of strategic developments, Alzamend Neuro has made notable progress in its clinical trials. The company initiated a Phase I/IIA clinical trial for ALZN002 in April 2023 and has partnered with Massachusetts General Hospital to conduct further studies on AL001. The company is also actively seeking additional funding to support its clinical development activities, as it anticipates continued operating losses until it can generate revenue from its product candidates. The filing indicates that the company plans to raise capital through public and private equity offerings and debt financing.

Operationally, Alzamend has seen changes in its equity structure, including the conversion of preferred stock into common stock, which has increased the number of common shares outstanding to 3,139,861 as of July 31, 2025. The company’s employee headcount remains modest, with four full-time and three part-time employees as of the end of the reporting period. The company continues to face challenges related to its liquidity and going concern status, as it will need to secure additional funding to sustain its operations and clinical programs.

Looking ahead, Alzamend Neuro acknowledges the need for substantial additional funding to support its ongoing clinical trials and operational needs. The company is focused on advancing its product candidates through clinical development while managing its financial resources carefully. The outlook remains cautious, with the company indicating that it expects to incur losses for the foreseeable future until it can achieve significant milestones in its product development and commercialization efforts.